Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans
RNS Number : 8663R Renalytix PLC 10 November 2021 Renalytix plc ("Renalytix" or the "Company") Renalytix Convenes Expert Panel at VA Healthcare Summit Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW
Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- St. Joseph's Health and Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to implement an
RNS Number : 7276R Renalytix PLC 09 November 2021 Renalytix plc ("Renalytix" or the "Company") St. Joseph's Health and Renalytix Partner to Advance Value-Based Kidney Health in New York Partnership expands doctor and patient access to advanced prognosis and coordinated care management of
RNS Number : 9254Q Renalytix PLC 01 November 2021 Renalytix plc (" Renalytix " or the " Company ") Issue of shares and Total Voting Rights NEW YORK , November 1, 2021 - Renalytix plc (AIM: RENX) announces that it has issued and allotted 68,224 ordinary shares of 0.25 pence each in the
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based
RNS Number : 7882P Renalytix PLC 21 October 2021 Renalytix plc (" Renalytix " or the " Company ") Renalytix Reports Full Year Fiscal 2021 Results LONDON and SALT LAKE CITY , October 21, 2021 - Renalytix plc (NASDAQ: RNLX), (LSE : RENX) an artificial intelligence-enabled in vitro
LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open.
RNS Number : 4032O Renalytix PLC 08 October 2021 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21 LONDON and SALT LAKE CITY , October 8, 2021 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced
Jed Fulk Appointed Vice President Sales, Government Accounts NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration
